CXCL13 and cancer: Under androgen ablation therapy, regressing PC is accompanied by cell death and hypoxia, which activates cancer-associated myofibroblasts (CAMF) to secrete CXCL13 by inducing HIF-1 activation and TGF-β expression [87].